Autres langues Atossa Therapeutics, Inc.

Actions

ATOS

US04962H5063

Temps réel estimé Cboe BZX Autres places de cotation 16:36:41 29/04/2024			Varia. 5j.	Varia. 1 janv.
1,555 ^USD	+1,63 %		+8,45 %	+75,00 %

14:30	Atossa Therapeutics, Inc. annonce un accord de recherche élargi avec Weill Cornell Medicine pour mieux évaluer la synergie entre les conjugués d'anticorps (ADC) et le (Z)-Endoxifen	CI
15/04	Atossa Therapeutics et Quantum Leap Healthcare Collaborative annoncent l'essai clinique I-SPY 2 visant à évaluer le (Z)-endoxifène en association avec l'abemaciclib (VERZENIO® ?) chez les femmes atteintes d'un cancer du sein ER+/HER2	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen	14:30
Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen	14:30
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer	16/04
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	15/04
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	15/04
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference	11/04
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	09/04
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	09/04
North American Morning Briefing : Stocks Seen -2-	02/04
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update	01/04
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient	20/03
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient	19/03
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient	19/03
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements	18/03
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors	12/03
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors	12/03
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting	06/03
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study	22/02
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment	22/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Atossa Therapeutics, Inc.

Actions

ATOS

US04962H5063

Autres langues

Filtres